22 results on '"Abayomi, Akin"'
Search Results
2. Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria
- Author
-
Abayomi, Akin, Odukoya, Oluwakemi, Osibogun, Akin, Wright, Ololade, Adebayo, Bisola, Balogun, Mobolanle, Abdus-Salam, Ismael, Bowale, Abimbola, Mutiu, Bamidele, Saka, Babatunde, Adejumo, Moyosore, Yenyi, Sam, Agbolagorite, Rotimi, Onasanya, Oluwatosin, Erinosho, Eniola, Obasanya, Joshua, Adejumo, Olu, Adesola, Sunday, Oshodi, Yewande, Akase, Iorhen E., Ogunbiyi, Shina, Lajide, Dayo, Erinoso, Femi, and Abdur-Razzaq, Hussein
- Published
- 2021
- Full Text
- View/download PDF
3. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
- Author
-
Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.
- Published
- 2021
- Full Text
- View/download PDF
4. ‘Long COVID’: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria
- Author
-
Osikomaiya, Bodunrin, Erinoso, Olufemi, Wright, Kikelomo Ololade, Odusola, Aina Olufemi, Thomas, Babafemi, Adeyemi, Oluwatosin, Bowale, Abimbola, Adejumo, Olusola, Falana, Ayodeji, Abdus-salam, Ismail, Ogboye, Olusegun, Osibogun, Akin, and Abayomi, Akin
- Published
- 2021
- Full Text
- View/download PDF
5. Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study
- Author
-
Abayomi, Akin, Osibogun, Akin, Kanma-Okafor, Oluchi, Idris, Jide, Bowale, Abimbola, Wright, Ololade, Adebayo, Bisola, Balogun, Mobolanle, Ogboye, Segun, Adeseun, Remi, Abdus-Salam, Ismael, Mutiu, Bamidele, Saka, Babatunde, Lajide, Dayo, Yenyi, Sam, Agbolagorite, Rotimi, Onasanya, Oluwatosin, Erinosho, Eniola, Obasanya, Joshua, Adejumo, Olu, Adesola, Sunday, Oshodi, Yewande, Akase, Iorhen E, Ogunbiyi, Shina, Omosun, Adenike, Erinoso, Femi, Abdur-Razzaq, Hussein, Osa, Nike, and Akinroye, Kingsley
- Published
- 2021
- Full Text
- View/download PDF
6. Addressing ethical issues in H3Africa research – the views of research ethics committee members
- Author
-
de Vries, Jantina, Abayomi, Akin, Littler, Katherine, Madden, Ebony, McCurdy, Sheryl, Ouwe Missi Oukem-Boyer, Odile, Seeley, Janet, Staunton, Ciara, Tangwa, Godfrey, Tindana, Paulina, Troyer, Jennifer, and The H3Africa Working Group on Ethics
- Published
- 2015
- Full Text
- View/download PDF
7. An assessment of geographical access and factors influencing travel time to emergency obstetric care in the urban state of Lagos, Nigeria.
- Author
-
Banke-Thomas, Aduragbemi, Wong, Kerry L M, Collins, Lindsey, Olaniran, Abimbola, Balogun, Mobolanle, Wright, Ololade, Babajide, Opeyemi, Ajayi, Babatunde, Afolabi, Bosede Bukola, Abayomi, Akin, Benova, Lenka, and Wong, Kerry Lm
- Subjects
HEALTH services accessibility ,TRAVEL ,POPULATION geography ,EMERGENCY medical services - Abstract
Previous efforts to estimate the travel time to comprehensive emergency obstetric care (CEmOC) in low- and middle-income countries (LMICs) have either been based on spatial models or self-reported travel time, both with known inaccuracies. The study objectives were to estimate more realistic travel times for pregnant women in emergency situations using Google Maps, determine system-level factors that influence travel time and use these estimates to assess CEmOC geographical accessibility and coverage in Lagos state, Nigeria. Data on demographics, obstetric history and travel to CEmOC facilities of pregnant women with an obstetric emergency, who presented between 1st November 2018 and 31st December 2019 at a public CEmOC facility were collected from hospital records. Estimated travel times were individually extracted from Google Maps for the period of the day of travel. Bivariate and multivariate analyses were used to test associations between travel and health system-related factors with reaching the facility >60 minutes. Mean travel times were compared and geographical coverage mapped to identify 'hotspots' of predominantly >60 minutes travel to facilities. For the 4005 pregnant women with traceable journeys, travel time ranges were 2-240 minutes (without referral) and 7-320 minutes (with referral). Total travel time was within the 60 and 120 minute benchmark for 80 and 96% of women, respectively. The period of the day of travel and having been referred were significantly associated with travelling >60 minutes. Many pregnant women living in the central cities and remote towns typically travelled to CEmOC facilities around them. We identified four hotspots from which pregnant women travelled >60 minutes to facilities. Mean travel time and distance to reach tertiary referral hospitals were significantly higher than the secondary facilities. Our findings suggest that actions taken to address gaps need to be contextualized. Our approach provides a useful guide for stakeholders seeking to comprehensively explore geographical inequities in CEmOC access within urban/peri-urban LMIC settings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. From Ebola to COVID-19: emergency preparedness and response plans and actions in Lagos, Nigeria.
- Author
-
Abayomi, Akin, Balogun, Mobolanle R., Bankole, Munir, Banke-Thomas, Aduragbemi, Mutiu, Bamidele, Olawepo, John, Senjobi, Morakinyo, Odukoya, Oluwakemi, Aladetuyi, Lanre, Ejekam, Chioma, Folarin, Akinsanya, Emmanuel, Madonna, Amodu, Funke, Ologun, Adesoji, Olusanya, Abosede, Bakare, Moses, Alabi, Abiodun, Abdus-Salam, Ismail, Erinosho, Eniola, and Bowale, Abimbola
- Subjects
- *
COVID-19 pandemic , *EBOLA virus disease , *EMERGENCY management , *COVID-19 , *DISEASE outbreaks - Abstract
Background: Lagos state is the industrial nerve centre of Nigeria and was the epicentre of the 2014 Ebola outbreak in Nigeria as it is now for the current Coronavirus Disease (COVID-19) outbreak. This paper describes how the lessons learned from the Ebola outbreak in 2014 informed the emergency preparedness of the State ahead of the COVID-19 outbreak and guided response.Discussion: Following the Ebola outbreak in 2014, the Lagos State government provided governance by developing a policy on emergency preparedness and biosecurity and provided oversight and coordination of emergency preparedness strategies. Capacities for emergency response were strengthened by training key staff, developing a robust surveillance system, and setting up a Biosafety Level 3 laboratory and biobank. Resource provision, in terms of finances and trained personnel for emergencies was prioritized by the government. With the onset of COVID-19, Lagos state was able to respond promptly to the outbreak using the centralized Incident Command Structure and the key activities of the Emergency Operations Centre. Contributory to effective response were partnerships with the private sectors, community engagement and political commitment.Conclusion: Using the lessons learned from the 2014 Ebola outbreak, Lagos State had gradually prepared its healthcare system for a pandemic such as COVID-19. The State needs to continue to expand its preparedness to be more resilient and future proof to respond to disease outbreaks. Looking beyond intra-state gains, lessons and identified best practices from the past and present should be shared with other states and countries. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Challenges in access and satisfaction with reproductive, maternal, newborn and child health services in Nigeria during the COVID-19 pandemic: A cross-sectional survey.
- Author
-
Balogun, Mobolanle, Banke-Thomas, Aduragbemi, Sekoni, Adekemi, Boateng, Godfred O., Yesufu, Victoria, Wright, Ololade, Ubani, Osinachi, Abayomi, Akin, Afolabi, Bosede B., and Ogunsola, Folasade
- Subjects
COVID-19 pandemic ,CHILD health services ,PANDEMICS ,INFANT health ,MEDICAL care ,CLIENT satisfaction - Abstract
Background: The presence of COVID-19 has led to the disruption of health systems globally, including essential reproductive, maternal, newborn and child health (RMNCH) services. This study aimed to assess the challenges faced by women who used RMNCH services in Nigeria's epicentre, their satisfaction with care received during the COVID-19 pandemic and the factors associated with their satisfaction. Methods: This cross-sectional survey was conducted in Lagos, southwest Nigeria among 1,241 women of reproductive age who had just received RMNCH services at one of twenty-two health facilities across the primary, secondary and tertiary tiers of health care. The respondents were selected via multi-stage sampling and face to face exit interviews were conducted by trained interviewers. Client satisfaction was assessed across four sub-scales: health care delivery, health facility, interpersonal aspects of care and access to services. Bivariate and multivariate analyses were used to assess the relationship between personal characteristics and client satisfaction. Results: About 43.51% of respondents had at least one challenge in accessing RMNCH services since the COVID-19 outbreak. Close to a third (31.91%) could not access service because they could not leave their houses during the lockdown and 18.13% could not access service because there was no transportation. The mean clients' satisfaction score among the respondents was 43.25 (SD: 6.28) out of a possible score of 57. Satisfaction scores for the interpersonal aspects of care were statistically significantly lower in the PHCs and general hospitals compared to teaching hospitals. Being over 30 years of age was significantly associated with an increased clients' satisfaction score (ß = 1.80, 95%CI: 1.10–2.50). Conclusion: The COVID-19 lockdown posed challenges to accessing RMNCH services for a significant proportion of women surveyed. Although overall satisfaction with care was fairly high, there is a need to provide tailored COVID-19 sensitive inter-personal care to clients at all levels of care. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Detection of SARS-CoV-2 in Nigeria: laboratory preparedness and report of index case.
- Author
-
James, Ayorinde Babatunde, Salu, Olumuyiwa Babalola, Shaibu, Joseph Ojonugwa, Onwuamah, Chika, Mutiu, Bamidele Paul, Amoo, Olufemi, Orenolu, Mercy Remilekun, Okwuraiwe, Azuka, Ndodo, Nnaemeka, Saka, Babatunde Akeem, Anyanwu, Roosevelt Amaobichukwu, Bankole, Munir Akinwale, Ige, Fehintola, Abdullah, Mariam Abiodun, Abdus-Salam, Ismail Adeshina, Audu, Rosemary Ajuma, Osibogun, Akin, Abayomi, Akin, Ihekweazu, Chikwe, and Salako, Babatunde Lawal
- Subjects
COVID-19 pandemic ,HEALTH facilities ,POLYMERASE chain reaction ,EVOLUTIONARY algorithms ,VACCINES - Abstract
Introduction: heightened surveillance of the severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) 2019 outbreak in Wuhan, China activated several collaborative laboratory drills on its detection by health institutions in Nigeria. We hereby detail the laboratory detection and confirmation of the novel SARS-CoV-2 virus of the index case imported into Nigeria. Methods: viral RNA from sputum sample of the index case was tested for SARS-CoV-2 envelope (E) and RNA dependent RNA polymerase (RdRp) genes using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Genetic analysis using a partial sequence of RdRp gene was used for laboratory confirmation, evolutionary inferences, and relatedness to previous strains of betacorona viruses in Nigeria. Results: both qRT-PCR for the E and RdRp genes indicated the presence of the SARSCoV-2 RNA by showing cycle threshold (ct) values of 20.27 and 25.26 respectively. On successful completion of the sequencing run, data aligned with >98% similarity of the 2019 circulating strain of Coronavirus SARS-CoV-2. Evolutionary algorithms revealed that the sequence (RdRp gene) of the outbreak circulating strains were more conserved unlike previous coronavirus outbreaks. Data showed that some coronaviruses belonging to the BetaCoV genus had earlier been reported in bats and camels in Nigeria indicating the possibility of sero-protection in exposed populations. Conclusion: pre-laboratory drills prompted early diagnosis and confirmation of SARS-CoV-2 index case in Nigeria initiating rapid case-definition, contact tracing, and successful epidemiological management of the outbreak. Rapid sequencing of the viral genome during strategic points of the outbreak curve and making libraries of new variants for improved vaccine development are recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria.
- Author
-
Osibogun, Akin, Balogun, Mobolanle, Abayomi, Akin, Idris, Jide, Kuyinu, Yetunde, Odukoya, Oluwakemi, Wright, Ololade, Adeseun, Remi, Mutiu, Bamidele, Saka, Babatunde, Osa, Nike, Lajide, Dayo, Abdus-Salam, Ismael, Osikomaiya, Bodunrin, Onasanya, Oluwatosin, Adebayo, Bisola, Oshodi, Yewande, Adesola, Sunday, Adejumo, Olu, and Erinoso, Olufemi
- Subjects
COVID-19 ,COMORBIDITY ,DEATH rate ,AFRICANS ,HYPERTENSION ,MEDICAL records - Abstract
Background: Data on the comorbidities that result in negative outcomes for people with COVID-19 are currently scarce for African populations. This study identifies comorbidities that predict death among a large sample of COVID-19 patients from Nigeria. Methods: This was a retrospective analysis of medical records for 2184 laboratory confirmed cases of COVID-19 in Lagos, southwest Nigeria. Extracted data included age, sex, severity of condition at presentation and self-reported comorbidities. The outcomes of interest were death or discharge from facility. Results: Most of the cases were male (65.8%) and the median age was 43 years (IQR: 33–55). Four hundred and ninety-two patients (22.5%) had at least one comorbidity and the most common amongst them were hypertension (74.2%) and diabetes (30.3%). The mortality rate was 3.3% and a significantly higher proportion of patients with comorbidities died compared to those with none. The comorbidities that predicted death were hypertension (OR: 2.21, 95%CI: 1.22–4.01), diabetes (OR: 3.69, 95% CI: 1.99–6.85), renal disease (OR: 12.53, 95%CI: 1.97–79.56), cancer (OR: 14.12, 95% CI: 2.03–98.19) and HIV (OR: 1.77–84.15]. Conclusion: Comorbidities are prevalent and the associated risk of death is high among COVID-19 patients in Lagos, Nigeria. Public enlightenment, early identification and targeted care for COVID-19 cases with comorbidities are recommended as the pandemic evolves. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Baobab Laboratory Information Management System: Development of an Open-Source Laboratory Information Management System for Biobanking.
- Author
-
Bendou, Hocine, Sizani, Lunga, Reid, Tim, Swanepoel, Carmen, Ademuyiwa, Toluwaleke, Merino-Martinez, Roxana, Meuller, Heimo, Abayomi, Akin, and Christoffels, Alan
- Abstract
A laboratory information management system (LIMS) is central to the informatics infrastructure that underlies biobanking activities. To date, a wide range of commercial and open-source LIMSs are available and the decision to opt for one LIMS over another is often influenced by the needs of the biobank clients and researchers, as well as available financial resources. The Baobab LIMS was developed by customizing the Bika LIMS software () to meet the requirements of biobanking best practices. The need to implement biobank standard operation procedures as well as stimulate the use of standards for biobank data representation motivated the implementation of Baobab LIMS, an open-source LIMS for Biobanking. Baobab LIMS comprises modules for biospecimen kit assembly, shipping of biospecimen kits, storage management, analysis requests, reporting, and invoicing. The Baobab LIMS is based on the Plone web-content management framework. All the system requirements for Plone are applicable to Baobab LIMS, including the need for a server with at least 8 GB RAM and 120 GB hard disk space. Baobab LIMS is a server-client-based system, whereby the end user is able to access the system securely through the internet on a standard web browser, thereby eliminating the need for standalone installations on all machines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Lessons Learned from Biospecimen Shipping Among the Human Heredity and Health in Africa Biorepositories.
- Author
-
Croxton, Talishiea, Swanepoel, Carmen, Musinguzi, Henry, Kader, Mukthar, Ozumba, Petronilla, Pillay, Azure-Dee, Syed, Raeesa, Swartz, Garth, Kyobe, Samuel, Lwanga, Newton, Katabazi, Fred Ashaba, Edgar, Kigozi, Ndidi, Agala, Jonathan, Emmanuel, Onyemata, Enzenwa, Isaacs, Shafieka, Mayne, Elizabeth Sarah, Joloba, Moses, Jentsch, Ute, and Abayomi, Akin
- Abstract
Background: Biospecimen shipping and handling challenges in Africa include climates that can potentially jeopardize sample integrity, and infrastructure and regulation limitations that affect courier reliability, access, and costs. There is a lack of investigations reporting on validation of standardized processes for biospecimen exchange among African countries and regions. The Human Heredity and Health in Africa (H3Africa) Initiative funded four African biorepositories (BR) to pilot test operations, and assess effectiveness of trans-African shipment of high-quality DNA, and other biospecimens for genomics research. Pilot studies tested the following: workflows and forms related to biospecimen exchange, transport logistics, and comparability and confirmation of quality control (QC) methods. Methods: Ethical and legal requirements for biospecimen, and data transfer were acquired before shipment. Biospecimens were collected and subjected to QC by the BR of origin before shipment, and by the recipient BR on arrival. Minimal QC requirements included concentration and purity for DNA. Paired Student's t-tests were used to determine significant differences in DNA concentrations, DNA purity, and urine pH pre- and postshipment. Results: The turnaround time for import/export permits was 21-90 days and material transfer agreements 1-10 months. There were nine shipments. Shipping duration averaged 5 days. Shipments sent at uncontrolled ambient temperature fluctuated between 5.6°C and 32.7°C. Seventy-seven percent of source DNA had purity ratios within the acceptable range before shipment. Eighty-nine percent of the DNA results did not differ significantly before and after shipment. Ninety-five percent of DNA extracted from shipped whole blood had acceptable purity. Conclusion: African BRs can collect, process, store, and ship biospecimens of good quality. This study shows it is possible to ship biospecimens between different regions of Africa in a reasonable time frame, without compromise to the cold chain and biospecimen integrity. It is also possible to harmonize ethical documents, guidelines, and processes among African BRs to facilitate collaboration. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Managing dangerous pathogens: challenges in the wake of the recent West African Ebola outbreak.
- Author
-
Abayomi, Akin, Katz, Rebecca, Spence, Scott, Conton, Brian, and Gevao, Sahr M.
- Subjects
PATHOGENIC microorganisms ,EBOLA virus disease ,BIOSECURITY ,BIOSAFETY ,PUBLIC health - Abstract
In the aftermath of the 2014–2016 West Africa Ebola outbreak, there are a multitude of Ebola samples that are unaccounted for as well as virus samples stored in facilities that do not have an appropriate level of biosecurity and biosafety, creating serious threats to public health and security. In this article, we review the existing global governance mechanisms for addressing this biosafety and biosecurity concern. We also describe an ongoing effort to support the Government of Sierra Leone to find and secure Ebola samples as foreign labs are shut down, and institute systems for biosafety and biosecurity. We describe the challenges of tracking all Ebola samples and their associated data, and efforts to place these samples in suitable inventoried repositories by local health authorities. We recommend that governments around the world ensure that plans, procedures and regulations are in place prior to the chaos of an emergency in order to ensure that dangerous pathogens are handled in safe and secure manners, that data are preserved for research, and appropriate practices are utilised for consent. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. African civil society initiatives to drive a biobanking, biosecurity and infrastructure development agenda in the wake of the West African Ebola outbreak.
- Author
-
Abayomi, Akin, Gevao, Sahr, Conton, Brian, Deblasio, Pasquale, and Katz, Rebecca
- Subjects
- *
CIVIL society , *BIOSECURITY , *EBOLA virus - Abstract
This paper describes the formation of a civil society consortium, spurred to action by frustration over the Ebola crises, to facilitate the development of infrastructure and frameworks including policy development to support a harmonized, African approach to health crises on the continent. The Global Emerging Pathogens Treatment Consortium, or GET, is an important example of how African academics, scientists, clinicians and civil society have come together to initiate policy research, multilevel advocacy and implementation of initiatives aimed at building African capacity for timely and effective mitigations strategies against emerging infectious and neglected pathogens, with a focus on biobanking and biosecurity. The consortium has been able to establish it self as a leading voice, drawing attention to scientific infrastructure gaps, the importance of cultural sensitivities, and the power of community engagement. The GET consortium demonstrates how civil society can work together, encourage government engagement and strengthen national and regional efforts to build capacity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Critical Issues in International Biobanking.
- Author
-
Vaught, Jim, Abayomi, Akin, Peakman, Tim, Watson, Peter, Matzke, Lise, and Moore, Helen
- Published
- 2014
- Full Text
- View/download PDF
17. Challenges of Biobanking in South Africa to Facilitate Indigenous Research in an Environment Burdened with Human Immunodeficiency Virus, Tuberculosis, and Emerging Noncommunicable Diseases.
- Author
-
Abayomi, Akin, Christoffels, Alan, Grewal, Ravnit, Karam, Locunda A., Rossouw, Catherine, Staunton, Ciara, Swanepoel, Carmen, and van Rooyen, Beverley
- Abstract
The high burden of infectious diseases and the growing problem of noncommunicable and metabolic disease syndromes in South Africa (SA) forces a more focused research approach to facilitate cutting-edge scientific growth and public health development. Increased SA research on these diseases and syndromes and the collection of associated biospecimens has ensured a plethora of biobanks created by individuals, albeit without the foresight of prospective and collective use by other local and international researchers. As the need for access to high-quality specimens in statistically relevant numbers has increased, so has the necessity for the development of national human biobanks in SA and across the Continent. The prospects of achieving sustainable centralized biobanks are still an emerging and evolving concept, primarily and recently driven by the launch of the H3Africa consortium, which includes the development of harmonized and standardized biobanking operating procedures. This process is hindered by a myriad of complex societal considerations and ethico-legal challenges. Efforts to consolidate and standardize biological sample collections are further compromised by the lack of full appreciation by national stakeholders of the biological value inherent in these collections, and the availability of high quality human samples with well-annotated data for future scientific research and development. Inadequate or nonexistent legislative structures that specifically regulate the storage, use, dispersal, and disposal of human biological samples are common phenomena and pose further challenges. Furthermore, concerns relating to consent for unspecified future uses, as well as access to information and data protection, are all new paradigms that require further consideration and public engagement. This article reviews important fundamental issues such as governance, ethics, infrastructure, and bioinformatics that are important foundational prerequisites for the establishment and evolution of successful human biobanking in South Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Chronic lymphocytic leukaemia trends and features at a tertiary hospital in South Africa (2011-2016).
- Author
-
Musaigwa, Fungai, Grewal, Ravnit, Abayomi, Akin, and Swanepoel, Carmen C.
- Subjects
- *
CHRONIC lymphocytic leukemia , *HIV , *CYTOGENETICS , *LYMPHOPROLIFERATIVE disorders , *CHROMOSOME abnormalities - Abstract
Background: Chronic lymphocytic leukaemia (CLL) is a common lymphoproliferative disorder in developed countries. However, this condition is rare in Africa and there is a paucity of information on CLL, specifically on the continent. Aim: This study described, retrospectively, the frequency, demographics and laboratory features of CLL cases diagnosed from 2011 to 2016. Setting: Department of Pathology, National Health Laboratory Service, Tygerberg Academic Hospital, Cape Town. Methods: A retrospective analysis was performed for all CLL diagnoses made between 01 January 2011 and 31 December 2016. Results: Eighty CLL cases were diagnosed between 2011 and 2016. Men and women presented with the disease equally (48.8% vs. 51.2%,p > 0.05). The mean age at diagnosis was 66.79 years (range of 37-95 years) and the modal age range (36.3%) was 60-69 years. Men presented with the disease at a significantly younger age than women (mean = 64 years vs. mean = 69.5 years, p < 0.05). There were three (3.75%) human immunodeficiency virus (HIV)-positive patients (age range 43-50 years). Chromosome 13q14 deletion was found in 6 out of 19 patients (31.6%). Trisomy 12 and deletion 11q22 were found in 5 out of 21 (24%) and 7 out of 21 (33.3%) patients, respectively. Deletions 13q34 and 17p were negative for 6 and 20 patients, respectively. Conclusion: Chronic lymphocytic leukaemia at our facility presented equally in men and women. Men presented with the disease at a younger age than women. Additionally, our findings suggested that HIV is uncommon amongst CLL patients tested for HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A perpetual source of DNA or something really different: ethical issues in the creation of cell lines for African genomics research.
- Author
-
de Vries, Jantina, Abayomi, Akin, Brandful, James, Littler, Katherine, Madden, Ebony, Marshall, Patricia, Ouwe Missi Oukem-Boyer, Odile, and Seeley, Janet
- Abstract
Background: The rise of genomic studies in Africa - not least due to projects funded under H3Africa - is associated with the development of a small number of biorepositories across Africa. For the ultimate success of these biorepositories, the creation of cell lines including those from selected H3Africa samples would be beneficial. In this paper, we map ethical challenges in the creation of cell lines.Discussion: The first challenge we identified relates to the moral status of cells living in culture. There is no doubt that cells in culture are alive, and the question is how this characteristic is relevant to ethical decision-making. The second challenge relates to the fact that cells in culture are a source of cell products and mitochondrial DNA. In combination with other technologies, cells in culture could also be used to grow human tissue. Whilst on the one hand, this feature increases the potential utility of the sample and promotes science, on the other it also enables further scientific work that may not have been specifically consented to or approved. The third challenge relates to ownership over samples, particularly in cases where cell lines are created by a biobank, and in a different country than where samples were collected. Relevant questions here concern the export of samples, approval of secondary use and the acceptability of commercialisation. A fourth challenge relates to perceptions of blood and bodily integrity, which may be particularly relevant for African research participants from certain cultures or backgrounds. Finally, we discuss challenges around informed consent and ethical review.Summary: In this paper, we sought to map the myriad of ethical challenges that need to be considered prior to making cell line creation a reality in the H3Africa project. Considering the relative novelty of this practice in Africa, such challenges will need to be considered, discussed and potentially be resolved before cell line creation in Africa becomes financially feasible and sustainable. We suggest that discussions need to be undertaken between stakeholders internationally, considering the international character of the H3Africa project. We also map out avenues for empirical research. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
20. A107 Lymphoma incidence and HIV-related lymphoma subtypes seen at Tygerberg Academic Hospital, Western Cape, South Africa, 2002-2011.
- Author
-
Abayomi, Akin, Stephens, Linda, Grewal, Ravnit, and Bassa, Fatima
- Abstract
The incidence of lymphomas in the Western Cape, a province of South Africa, with a population of 5 million and a HIV prevalence of 17% is undocumented. Antiretroviral therapy (ART) was introduced into the public patient sector in 2004 with 34% estimated coverage by 2010. People living with HIV (PLWH) have a significant increased risk of developing HIV-related lymphoma (HRL). Therefore, HRL would be expected to increase but retard with introduction of ART. The pattern of the impact of HIV and effect of introduction of ART is investigated.We reviewed all patients diagnosed with malignant lymphoma (ML) from the Tygerberg Hospital catchments area in the Western Cape of South Africa for years 2002-2011. In this time frame 900 cases of ML were identified of which 710 were HIV negative and 190 HIV positive. ML were sub-typed according to WHO classification, based on morphology, molecular and immunophenotypic platforms.ML cases increased steadily with each year from 2002 to 2011. Despite the introduction of an aggressive ART roll out program in 2004, HRL increased steadily from 4% in 2002 to 28% in 2011 with a profile of subtypes differing from the HIV negative cases. There is a predominance of Diffuse Large B Cell Lymphoma and Burkitt Lymphoma in the HIV positive cohort. The range of the CD4 count at presentation in a smaller cohort studied between 2010 and 2011 was from 20 to 620, with an average count of 150.These findings are in contrast to the observed pattern of reduced incidence of HRL in the developed world with the introduction of ART. This warrants evaluation in the manner and timing of introduction of ART in South Africa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Taking the bull by the horns: Ethical considerations in the design and implementation of an Ebola virus therapy trial.
- Author
-
Kombe, Francis, Folayan, Morenike O., Ambe, Jennyfer, Igonoh, Adaora, and Abayomi, Akin
- Subjects
- *
PREVENTION of epidemics , *ETHICS , *EXPERIMENTAL design ,TREATMENT of Ebola virus diseases - Abstract
Ebola virus is categorized as one of the most dangerous pathogens in the world. Although there is no known cure for Ebola virus, there is some evidence that the severity of the disease can be curtailed using plasma from survivors. Although there is a general consensus on the importance of research, methodological and ethical challenges for conducting research in an emergency situation have been identified. Performing clinical trials is important, especially for health conditions that are of public health significance (including rare epidemics) to develop new therapies as well as to test the efficacy and effectiveness of new interventions. However, routine clinical trial procedures can be difficult to apply in emergency public health crises hence require a consideration of alternative approaches on how therapies in these situations are tested and brought to the market. This paper examines some of the ethical issues that arise when conducting clinical trials during a highly dangerous pathogen outbreak, with a special focus on the Ebola virus outbreak inWest Africa. The issues presented here come from a review of a protocol that was submitted to the Global Emerging Pathogens Treatment Consortium (GET). In reviewing the proposal, which was about conducting a clinical trial to evaluate the safety and efficacy of using convalescent plasma in the management of Ebola virus disease, the authors deliberated on various issues, which were documented as minutes and later used as a basis for this paper. The experiences and reflections shared by the authors, who came from different regions and disciplines across Africa, present wide-ranging perspectives on the conduct of clinical trials during a dangerous disease outbreak in a resource-poor setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. The H3Africa policy framework: negotiating fairness in genomics.
- Author
-
de Vries, Jantina, Tindana, Paulina, Littler, Katherine, Ramsay, Michèle, Rotimi, Charles, Abayomi, Akin, Mulder, Nicola, and Mayosi, Bongani M.
- Subjects
- *
HUMAN heredity , *GENOMICS , *PUBLIC health , *HEALTH policy , *FAIRNESS - Abstract
Human Heredity and Health in Africa (H3Africa) research seeks to promote fair collaboration between scientists in Africa and those from elsewhere. Here, we outline how concerns over inequality and exploitation led to a policy framework that places a firm focus on African leadership and capacity building as guiding principles for African genomics research. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.